Navigation Links
ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity

Chicago, IL and San Jose, CA, June 7, 2010 Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. In this new study of 575 individuals, Chronix's proprietary assays detected and identified DNA fingerprints in the blood that indicated the presence of prostate cancer and breast cancer with 92% sensitivity and 100% specificity, significantly outperforming the published accuracy data for current diagnostic methods. The new study results were presented in an oral session today at the 2010 ASCO Annual Meeting in Chicago.

Breast cancer expert, Steven Narod, M.D., F.R.C.P.C., noted, "These new data, although early, provide further evidence that Chronix's proprietary serum DNA assays may represent a new diagnostic and prognostic platform that can identify cancer earlier and more accurately than is currently possible. I am pleased to be working with Chronix to further validate these promising findings." Dr. Narod is Director of the Familial Breast Cancer Research Unit at Women's College Research Institute, an affiliate of the University of Toronto.

The tests use proprietary algorithms developed by Chronix researchers to detect, analyze and identify cancer-related fragments of circulating DNA that are released into the bloodstream by apoptotic cells. Chronix researchers consistently find that this apoptotic DNA in the serum is coming from a limited number of regions or "hotspots" on the genome specific to each cancer. According to the data presented today, DNA fragments from any one of the 29 breast cancer "hotspots" and 32 prostate cancer "hotspots" identified by Chronix researchers indicate that cancer is present.

"By focusing on these blood-borne genomic 'hotspots,' we can reliably detect the presence of cancer without having to first isolate or analyze the tumor cells," said Howard Urnovitz, Ph.D., Chief Executive Officer of Chronix and a co-author of the study. "If verified by further studies, our Chronix blood-based assays would make it possible to diagnose cancer at its earliest stages, track progress as patients undergo treatment and possibly even optimize treatment using patients' disease-specific genomic fingerprints."

The testing involved 575 individuals: 178 with early stage breast cancer, 197 with invasive prostate cancer and 200 healthy controls. The Chronix assays detected breast cancer with a 92% sensitivity and 100% specificity. Although not directly comparable, for reference it is noteworthy that data from a large study of U.S. mammography screening programs reported an overall sensitivity of just 75%, and specificity of 92.3%, with lower figures for some populations such as younger women. The Chronix assays also detected invasive prostate cancer with a 92% sensitivity and 100% specificity. In contrast, the widely used PSA (prostate specific antigen) test has previously demonstrated 85% sensitivity and a specificity of just 25% to 35%. If the Chronix data are confirmed in larger studies, they have the potential to reduce the current rate of false positive and false negative results that contribute to poorer patient outcomes and higher health care costs.

Previous published studies have demonstrated that the Chronix approach can identify the presence or absence of active disease in multiple sclerosis patients and that it can accurately detect early stage breast cancer with high diagnostic sensitivity and specificity. Commercial applications for veterinary use are already in development in conjunction with the University of Calgary, including tests for the early detection of BSE, or mad cow disease.

Dr. Urnovitz added, "With these encouraging findings, we are launching a 'For Investigative Use Only' testing service that for the first time will enable cancer researchers to monitor the status of patients in their clinical trials with a high level of sensitivity and specificity, potentially accelerating clinical trials and increasing their chances for success."

Patient data collected from this new service for clinical researchers along with additional planned clinical studies are expected to expand the database needed to obtain regulatory approval for the use of Chronix assays in ongoing cancer patient care.


Contact: Barbara Lindheim
BioCom Partners

Related medicine news :

1. Cosmetic Peptides that Significantly Reduce Length and Depth of Wrinkles: Janet Sartin Introduces Advanced Anti-Wrinkle Peptide Serum for All Skin Types
2. Blood stem-cell transplant regimen reverses sickle cell disease in adults
3. Blood Thinner Combos Risky for Heart Attack Patients
4. China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
5. A better sign of blood vessel narrowing and early coronary artery disease
6. American Red Cross and Other U.S. Blood Centers Send Blood to Haiti
7. Analysis Examines Ultrasound Use for Blood Clots
8. Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive
9. Newly discovered mechanism by which blood clots form
10. Long Before Symptoms, Blood May Reveal Rheumatoid Arthritis
11. Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of Excellence in the Life Sciences Initiative aimed at enhancing Purdue’s life sciences ... $2 billion “Ever True” capital campaign. , The investment will result in cohesive ...
(Date:10/13/2015)... West Palm Beach, FL (PRWEB) , ... October 13, 2015 , ... ... acquisition of Global Laser Vision of San Diego, California. With brands including The LASIK ... 3.3 million successful procedures, making it the nationwide leader in laser vision correction. , ...
(Date:10/13/2015)... N.J. (PRWEB) , ... October 13, 2015 , ... ... media enterprise focused on cancer patients, today announced a new partnership with the ... patients battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... beverage companies in the United States, today announced the release of its limited ... and new Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a ... delivers innovative health programs and interventions via mobile devices that provide a framework ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... VEGAS , Oct. 13, 2015 VIVA ... of vascular medicine and intervention through education and research, ... annual conference,  VIVA 2015 . Sixteen trial results, featuring ... released for the first time on Monday and Tuesday, ... --> --> Since ...
(Date:10/13/2015)... , Oct. 13, 2015  Kay Elledge, ... and Fellow American College of Obstetrics and Gynecology ... evolve by establishing the Genuine Self Medical Laser ... and men.  In recognition of Breast Cancer ... special promotion for MonaLisa Touch treatments ...
(Date:10/13/2015)... PITTSBURGH , Oct. 13, 2015  Mylan N.V. (Nasdaq: ... at 5:00 p.m. ET host a conference call and webcast ... Company plc (NYSE: PRGO ; TASE) shareholders through Mylan,s ... by Mylan,s Executive Chairman Robert J. Coury , CEO ... --> --> Mylan ...
Breaking Medicine Technology: